The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies that have fueled widespread use of the knockoffs have other plans, The Wall Street Journal’s Liz Essley Whyte reports. Hims & Hers Health (HIMS) will keep offering compounded versions of Ozempic and Wegovy tweaked to individual prescriptions, while some pharmacies making the GLP-1 drug copycats will continue, according to the report. Production of pharmacy-prepared versions of Eli Lilly’s (LLY) Zepbound were supposed to have stopped on Wednesday, and later in the spring for knockoffs of Novo Nordisk (NVO) Ozempic and Wegovy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching Barrier
- Hims & Hers price target raised to $22 from $21 at BofA
- Sell Rating for Hims & Hers Health Amid Slowing Core Business Growth and Legal Challenges
- Hims & Hers Health’s (HIMS) App Downloads Surged in February, Says Top Analyst
- FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss